Clinical Trial Update: Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma [Phase 1]

View source ↗

Summary

Phase 1 trial sponsored by the National Cancer Institute evaluated the combination of magrolimab and dinutuximab in pediatric patients with relapsed or refracto…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma
• Osteosarcoma

Drugs mentioned

• Magrolimab (magrolimab)
• dinutuximab (dinutuximab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: High Risk Neuroblastoma, Recurrent Neuroblastoma | Phase 1 | Status: COMPLETED | Results posted: 2026-01-21